GERO
Updated: June 20, 2026
CEO and cofounder Peter Fedichev
Country: Singapore | Funding: $35.7M (+)
Founded: 2018
Website: http://gero.com/
Gero is developing an AI-driven drug discovery platform focused on slowing aging and treating chronic diseases. It creates AI models of aging based on large-scale, real-life longitudinal data, integrating clinical, molecular, omics, and genetic signals with physically based modeling, and identifies targets directly in human health data. These targets are then tested in known disease models. Company's programs considered for preclinical development include oncology and fibrosis.
Founded: 2018
Website: http://gero.com/
Gero is developing an AI-driven drug discovery platform focused on slowing aging and treating chronic diseases. It creates AI models of aging based on large-scale, real-life longitudinal data, integrating clinical, molecular, omics, and genetic signals with physically based modeling, and identifies targets directly in human health data. These targets are then tested in known disease models. Company's programs considered for preclinical development include oncology and fibrosis.
